Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

241. Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review

Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review Fernandes Moca Trevisani V, Riera R, Mizusaki Imoto A, Saconato H, Atallah A N CRD summary The authors concluded that intermittent low-dose (...) osteoporosis. Searching MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, LILACS and congress abstracts in the areas of rheumatology, orthopaedics and bones were searched. Search dates varied across sources and spanned 1996 to January 2005. Search terms were reported. Pharmaceutical companies were contacted for unpublished data. Study selection Randomised controlled trials (RCTs) that evaluated the effect of teriparatide on bone mineral density and fractures in women with a natural or surgically

2008 DARE.

242. Tai chi for osteoporosis: a systematic review

Tai chi for osteoporosis: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

243. Percutaneous vertebroplasty or kyphoplasty for vertebral fractures caused by osteoporosis or malignancy

Percutaneous vertebroplasty or kyphoplasty for vertebral fractures caused by osteoporosis or malignancy Percutaneous vertebroplasty or kyphoplasty for vertebral fractures caused by osteoporosis or malignancy Percutaneous vertebroplasty or kyphoplasty for vertebral fractures caused by osteoporosis or malignancy BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation BlueCross BlueShield Association. Percutaneous vertebroplasty or kyphoplasty for vertebral fractures caused by osteoporosis or malignancy. Chicago IL: BlueCross BlueShield Association (BCBS). TEC Assessment 23(5). 2008 Authors' objectives To evaluate the evidence to determine whether vertebroplasty or kyphoplasty is an effective procedure to alleviate the symptoms from vertebral fractures caused by osteoporosis or malignancy. Authors' conclusions There is a lack of rigorous

2008 Health Technology Assessment (HTA) Database.

244. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations

Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations Tosteson AN, Burge RT, Marshall DA, Lindsay R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of various bisphosphonate treatments versus no intervention or parathyroid hormone for post-menopausal women with osteoporosis, who were at various levels of risk of fractures, based on age and history of previous vertebral fracture. The authors concluded that osteoporosis

2008 NHS Economic Evaluation Database.

245. Cost-effective osteoporosis treatment thresholds: the United States perspective Full Text available with Trip Pro

Cost-effective osteoporosis treatment thresholds: the United States perspective Cost-effective osteoporosis treatment thresholds: the United States perspective Cost-effective osteoporosis treatment thresholds: the United States perspective Tosteson A N, Melton L J, Dawson-Hughes B, Baim S, Favus M J, Khosla S, Lindsay R L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study aimed to identify the 10-year hip fracture probability required for osteoporosis treatment to be cost-effective for different cohorts of patients defined by their age, sex, and race or ethnicity. The osteoporosis treatment was cost-effective, at a willingness to pay of $60,000 per quality-adjusted life-year, when the 10-year hip fracture probability

2008 NHS Economic Evaluation Database.

246. The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden

The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden Zethraeus N, Strom O, Borgstrom F, Kanis J A, Jonsson B Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study assessed the cost-effectiveness of treatment of osteoporosis, hypertension, and hyperlipidaemia in different high-risk female populations aged 50 to 80 years. A five-year cholesterol-lowering, antihypertensive, and osteoporosis treatment was cost-effective

2008 NHS Economic Evaluation Database.

247. A coordinator program in post-fracture osteoporosis management improves outcomes and saves costs Full Text available with Trip Pro

A coordinator program in post-fracture osteoporosis management improves outcomes and saves costs A coordinator program in post-fracture osteoporosis management improves outcomes and saves costs A coordinator program in post-fracture osteoporosis management improves outcomes and saves costs Sander B, Elliot-Gibson V, Beaton D E, Bogoch E R, Maetzel A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the clinical and economic impact of an osteoporosis coordinator to manage patients with a fragility fracture and to coordinate their education, assessment, referral, and further treatment of the underlying osteoporosis. The authors concluded that having a coordinator in a tertiary care centre reduced

2008 NHS Economic Evaluation Database.

248. Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective

Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective Wasserfallen J B, Krieg M A, Greiner R A, Lamy O Record Status This is a critical abstract (...) . The remaining scenario with a incremental cost-utility ratio of more than 45,000 euro was in women aged 65 years with no pre-existing risk factors and no assumed residual effects post-treatment. Age at the start of therapy and the fracture risk profile had a significant impact on the results. Authors' conclusions The authors concluded that, assuming a two-year residual effect, the incremental cost-utility ratio of risedronate in women with postmenopausal osteoporosis was within the accepted thresholds from

2008 NHS Economic Evaluation Database.

249. An economic evaluation of quantitative ultrasonometry as pre-screening test for the identification of patients with osteoporosis

An economic evaluation of quantitative ultrasonometry as pre-screening test for the identification of patients with osteoporosis An economic evaluation of quantitative ultrasonometry as pre-screening test for the identification of patients with osteoporosis An economic evaluation of quantitative ultrasonometry as pre-screening test for the identification of patients with osteoporosis Hiligsmann M, Ethgen O, Bruyere O, Reginster JY Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of pre-screening for osteoporosis using several quantitative ultrasound index thresholds to identify those at risk. The authors concluded that quantitative ultrasound could be useful as a pre

2008 NHS Economic Evaluation Database.

250. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model

Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model Kreck S, Klaus J (...) with sodium fluoride plus calcium/colecalciferon and calcium/colecalciferon alone, to prevent osteopoenic or osteoporotic fracture risk in patients with inflammatory bowel disease in Germany, investigating patients of different age groups and with different severity levels of osteoporosis. The most cost-effective treatment was calcium monotherapy, while ibandronate plus calcium/colecalciferon was not economically attractive. The quality of the study methodology was very high in terms of the sources used

2008 NHS Economic Evaluation Database.

251. The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis

The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis Ding H, Koinuma N, Stevenson M, Ito M, Monma Y Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of bone mineral density scans for women aged 55 years and over followed by treatment with risedronate for those who have osteoporosis. Scanning and treatment for women aged 70 years and over, who had a vertebral fracture in the previous two years, was cost-effective in the Japanese setting, but not for women without previous fractures. The analysis

2008 NHS Economic Evaluation Database.

252. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands

Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom (...) and The Netherlands Jansen J P, Gaugris S, Bergman G, Sen S S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to evaluate the cost-effectiveness of treatments for osteoporosis in the UK and the Netherlands. The authors concluded

2008 NHS Economic Evaluation Database.

253. Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis

Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis Mueller D, Weyler E, Gandjour A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to determine the cost-effectiveness of a screening and treatment strategy, for postmenopausal osteoporosis, versus no intervention. The authors concluded that alendronate treatment with screening appeared to be cost-effective. Overall the methodology was good, and the methods and results were adequately reported. Given the scope of the analysis, the authors

2008 NHS Economic Evaluation Database.

254. Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women

Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women Mueller D, Gandjour A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to determine the cost-effectiveness of osteoporosis screening in women aged 50 to 90 years. The authors concluded that quantitative ultrasound then dual X-ray absorptiometry (DXA) was cost-effective compared with no screening. DXA alone was also cost-effective compared with quantitative ultrasound then DXA, except for women aged 60

2008 NHS Economic Evaluation Database.

255. Development and internal validation of the male osteoporosis risk estimation score. Full Text available with Trip Pro

Development and internal validation of the male osteoporosis risk estimation score. PURPOSE: We wanted to develop and validate a clinical prediction rule to identify men at risk for osteoporosis and subsequent hip fracture who might benefit from dual-energy x-ray absorptiometry (DXA). METHODS: We used risk factor data from the National Health and Nutrition Examination Survey III to develop a best fitting multivariable logistic regression model in men aged 50 years and older randomized to either (...) the development (n = 1,497) or validation (n = 1,498) cohorts. The best fitting model was transformed into a simplified scoring algorithm, the Male Osteoporosis Risk Estimation Score (MORES). We validated the MORES, comparing sensitivity, specificity, and area under the receiver operating characteristics (ROC) curve in the 2 cohorts and assessed clinical utility with an analysis of the number needed-to-screen (NNS) to prevent 1 additional hip fracture. RESULTS: The MORES included 3 variables-age, weight

2007 EvidenceUpdates

256. Subclinical hypercortisolism among outpatients referred for osteoporosis. (Abstract)

Subclinical hypercortisolism among outpatients referred for osteoporosis. Hypercortisolism is known to cause osteoporosis.To evaluate the prevalence of subclinical hypercortisolism in participants referred for evaluation of osteoporosis.Cross-sectional study.Two community hospitals and research institutes in Italy.219 patients without clinically overt hypercortisolism or other secondary causes of osteoporosis who were referred for evaluation of osteoporosis between January 2005 and December (...) with osteoporosis. In multivariable analyses adjusted for age, sex, and body mass index, a positive dexamethasone suppression test result was associated with the presence of osteoporosis (odds ratio, 3.37 [CI, 1.78 to 6.43]; P < 0.001) and vertebral fractures (odds ratio, 1.70 [CI, 1.04 to 2.79]; P = 0.035).The study was conducted in a referral setting; its findings may not apply to the general population.Subclinical hypercortisolism may be more common than is generally recognized in patients with osteoporosis

2007 Annals of Internal Medicine

257. WITHDRAWN: Etidronate for treating and preventing postmenopausal osteoporosis. (Abstract)

WITHDRAWN: Etidronate for treating and preventing postmenopausal osteoporosis. Osteoporosis is a clinical syndrome of reduced bone mass and increased fracture susceptibility. There are now a number of options, including etidronate which can decrease the risk of fractures.To systematically review the efficacy of etidronate on bone density, fractures and toxicity in postmenopausal women.We searched MEDLINE from 1966 to December 1998, examined citations of relevant articles, and the proceedings (...) of international osteoporosis meetings. We contacted osteoporosis investigators to identify additional studies, primary authors, and pharmaceutical industry sources for unpublished data.We included thirteen trials (with 1010 participants) that randomized women to etidronate or an alternative (placebo or calcium and/or vitamin D) and measured bone density for at least one year.For each trial, three independent reviewers assessed the methodological quality and abstracted data.The data suggested a reduction

2007 Cochrane

258. WITHDRAWN: Risedronate for the prevention and treatment of postmenopausal osteoporosis. (Abstract)

WITHDRAWN: Risedronate for the prevention and treatment of postmenopausal osteoporosis. Postmenopausal osteoporosis results in an increased susceptibility to low-trauma fractures due to reduced bone volume and microarchitectural deterioration. Risedronate, a third generation bisphosphonate, has been shown in multiple clinical trials to reduce fracture risk and improve bone mineral density in postmenopausal women with osteoporosis. First and second generation bisphosphonates are known to have (...) gastrointestinal side-effects and risedronate may be better tolerated.To systematically review the efficacy of risedronate on bone density, and fracture reduction in postmenopausal women.The Cochrane Controlled Trials Registry Medline, and Current Contents were searched from 1990 - 2001. The electronic search was supplemented by handsearching four osteoporosis journals and their conference proceedings, as well as contacting content experts and industry sources for unpublished data.We included eight trials

2007 Cochrane

259. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. Full Text available with Trip Pro

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period.In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 (...) mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral fracture (in patients not taking concomitant osteoporosis medications) and hip fracture (in all patients). Secondary end points included bone mineral density, bone turnover markers, and safety outcomes.Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared

2007 NEJM Controlled trial quality: predicted high

260. Screening Men for Osteoporosis

Screening Men for Osteoporosis Evidence Synthesis Pilot Program Screening Men for Osteoporosis: Who & How Department of Veterans Affairs Health Services Research & Development Service May 2007 Investigators: Paul Shekelle, MD, PhD Director Brett Munjas, BA Project Manager/Literature Database Manager Hau Liu, MD Elaine Wong, MD Content Experts/Physician Reviewers Neil Paige, MD Caroline Goldzweig, MD Physician Reviewers/Health Services Researchers Annie Zhou, MS Marika Suttorp, MS Statisticians (...) Prepared for: Department of Veterans Affairs Veterans Health Administration Health Services Research & Development Service Washington, DC 20420 Prepared by: Greater Los Angeles Veterans Affairs Healthcare System/Southern California/RAND Evidence-based Practice Center Los Angeles, CA ii Suggested Citation Shekelle P, Munjas B, Liu H, Paige N, and Zhou A. “Screening Men for Osteoporosis: Who & How.” Department of Veterans Affairs. May 2007. Technical Experts & Consultants* Eric Orwoll, MD, Oregon Health

2007 Veterans Affairs Evidence-based Synthesis Program Reports